BridgeBio Pharma (BBIO) Q2 Earnings, Revenue Exceed Estimates, Despite Losses

BridgeBio Pharma (BBIO) reported second-quarter 2026 results on August 10, posting revenue of $243.7 million that beat analyst estimates of roughly $218.7 million, even as the company posted a wider than expected net loss.

The results highlight how quickly Attruby (acoramidis), BridgeBio's therapy for transthyretin amyloid cardiomyopathy, has become the company's commercial anchor. Attruby's rapid uptake is now funding a slate of additional near-term product launches the company has framed as "Launch 2.0."

Attruby generated $222.4 million in U.S. net product revenue in the quarter, up 211% year over year, helping drive total revenue growth of roughly 120% from a year ago. That growth came alongside a net loss attributable to shareholders of $152.2 million, or $0.78 per share, wider than the $0.60 per share loss analysts had modeled, as operating expenses climbed to $335.7 million. BridgeBio ended the quarter with $720.2 million in cash and marketable securities, a figure that could grow to roughly $1.7 billion pro forma for the $1 billion preferred equity financing it closed July 1.

Shares traded well below GuruFocus's GF Value estimate, implying the stock could be undervalued by as much as 45.9%, and one analyst raised a 12-month price target to $109.18, implying about 29% upside from current levels. Investors may want to watch whether three pending regulatory submissions, for BBP-418, encaleret, and oral infigratinib, can replicate Attruby's early launch trajectory over the coming year.

Related Stocks

• BBIO